Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02337426 : Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
PhasePhase 1
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Histopathologically proven diagnosis of glioblastoma or gliosarcoma (World Health
Organization [WHO] grade IV) following either a surgical resection or biopsy

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Subjects must have recovered from surgery or biopsy before study registration

- Therapy must begin between 21 days (3 weeks) and 42 days (6 weeks) after the most
recent brain tumor surgery(resection or biopsy)

- Documentation of steroid doses 10-14 days prior to study registration and stable or
decreasing steroid dose over the week prior to registration

- Absolute neutrophil count (ANC) >= 1500/mm^3

- Platelets >= 100,000/mm^3 (untransfused)

- Hemoglobin >= 10 g/dL (the use of transfusion or other intervention to achieve
hemoglobin >= 10 g/dL is acceptable)

- Creatinine =< 1.5 x upper limit of normal (ULN) for the laboratory or calculated or
actual creatinine clearance > 45 mL/min

- Total bilirubin =< 1.5 x ULN for the laboratory (total bilirubin criteria may be
waived if a subject has documented Gilbert's syndrome)

- Aspartate aminotransferase (AST) =< 3 x ULN for the laboratory

- Alanine aminotransferase (ALT) =< 3 x ULN for the laboratory

- Women of childbearing potential and male subjects must practice adequate
contraception

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Prior invasive malignancy (except for non-melanoma skin cancer) unless disease free
for >= 3 years

- Recurrent malignant gliomas

- Metastases detected below the tentorium or beyond the cranial vault

- Prior chemotherapy or radiation therapy (RT) for the diagnosis of GBM or for cancers
of the head and neck

- Clinically significant cardiac disease, including major cardiac dysfunction, such as
uncontrolled angina, clinical congestive heart failure with New York Heart
Association (NYHA) class III or IV, ventricular arrhythmias requiring anti-arrhythmic
therapy

- Pregnant or lactating women

- History of allergic reactions or intolerance to any of the required agents on the
study

- History of hypersensitivity to dacarbazine

- Any treatment for GBM, other than surgery or anti-epileptic therapy, within 30 days
prior to study treatment initiation

- Other condition(s) that in the opinion of the investigator might compromise the
objectives of the study or increase patient risk
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02337426      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740